A pharmaceutical formulation of the cannabis extract, cannabidiol is being developed for those patients who do not respond to previous treatments for seizures associated with Lennox-Gastaut syndrome. This is taken as an oral solution.
Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults
Indications: Lennox-Gastaut syndrome
Therapeutic Areas: Neurology